| 摘要 |
The present invention relates to a crystalline form of compound (I), 4-{(1S,2S)-2-[(4-cyclobutylpiperazin-1-yl)carbonyl]-cyclopropyl}-benzamide, pharmaceutical formulations containing said compound and to the use of said active compound in therapy.
|
